HC Wainwright Estimates Atossa Genetics FY2030 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Research analysts at HC Wainwright issued their FY2030 earnings estimates for Atossa Genetics in a report released on Thursday, March 26th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.15) for the year. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share.

Several other research analysts have also commented on ATOS. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. Ascendiant Capital Markets lifted their price objective on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $68.33.

Atossa Genetics Stock Up 0.2%

Shares of NASDAQ ATOS opened at $4.72 on Friday. The stock has a market capitalization of $40.64 million, a PE ratio of -1.31 and a beta of 1.42. The firm has a fifty day moving average of $5.71 and a 200-day moving average of $9.92. Atossa Genetics has a 52-week low of $3.76 and a 52-week high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC boosted its stake in Atossa Genetics by 39.9% during the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after purchasing an additional 72,235 shares during the period. Bank of America Corp DE increased its position in Atossa Genetics by 55.8% in the 3rd quarter. Bank of America Corp DE now owns 155,169 shares of the company’s stock worth $135,000 after buying an additional 55,568 shares during the period. Graham Capital Management L.P. increased its position in Atossa Genetics by 27.8% in the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock worth $125,000 after buying an additional 45,923 shares during the period. XTX Topco Ltd lifted its holdings in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after buying an additional 144,412 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Atossa Genetics by 1,294.2% during the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors.

Atossa Genetics News Summary

Here are the key news stories impacting Atossa Genetics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and a $25.00 price target on ATOS, a clear positive signal for investors and a likely contributor to upward momentum. MarketBeat ATOS Coverage
• Positive Sentiment: Analyst model improvements for FY2027–FY2029 and FY2030: HC Wainwright substantially reduced projected multi‑year losses (e.g., FY2027 moved to ($0.61) from a much larger loss, FY2028 to ($0.40) from ($3.45), FY2029 to ($0.20) from ($2.70), and FY2030 to ($0.15)), implying a faster path toward lower losses/nearer break‑even — a bullish long‑term signal. MarketBeat ATOS Coverage
• Positive Sentiment: HC Wainwright slightly improved FY2026 and FY2028–FY2029 EPS forecasts overall (FY2026 moved to ($4.75) from ($4.95)), signaling modestly better near‑term expectations versus prior forecasts. MarketBeat ATOS Coverage
• Neutral Sentiment: Media coverage summarized the analyst call and framed the update as a catalyst for expected upside; this helps visibility but doesn’t add new company‑level information. Atossa Genetics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Negative Sentiment: Near‑term quarterly outlooks were worsened: HC Wainwright increased expected losses for Q1 and Q2 2026 (Q1 to ($1.34) from ($1.20); Q2 to ($1.45) from ($1.20)), which could weigh on sentiment and short‑term performance if investors focus on immediate cash burn and dilution risks. MarketBeat ATOS Coverage

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.